• 제목/요약/키워드: immunomodulator

검색결과 127건 처리시간 0.027초

Cytotoxic Constituents from Amanita pantherina(DC. ex Fr.) Krombh

  • Hong, Soon-Yong;Moon, Hyung-In;Zee, Ok-Pyo
    • 대한약학회:학술대회논문집
    • /
    • 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
    • /
    • pp.373.2-373.2
    • /
    • 2002
  • In search for plant-derived cytotoxic compounds, it was found that the MeOH extracts obtained from Amanita pantherina(DC. ex Fr.) Krombh exhibited significant cytotoxic activity against human tumor cell line. The classical fractionation on the basis of the inhibitory activity upon the growth human tumor cell line. in vitro, and repeated column chromatography afforded several cytotoxic compounds from Amanita pantherina (DC, ex Fr.) Krombh. (omitted)

  • PDF

Practical Synthesis of $\alpha$-Galactosyl Ceramide, KRN 7000.

  • Song, So-Young;Jung, Song-Kyu;Kim, Sang-Hee
    • 대한약학회:학술대회논문집
    • /
    • 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2-2
    • /
    • pp.175.1-175.1
    • /
    • 2003
  • Galactosyl ceramides paly important roles in biological system as immunomodulator and essential constituents of membranes and cell walls. An efficient synthesis of $\alpha$-galactosyl ceramide, KRN 7000, derived from marine sponge Agelas mauritianus as accomplished via a short reaction involving the coupling ceramide moiety and trichloroacetimidate as glycosylation donor. We could synthesize $\alpha$-galactosyl ceramide stereoselectivity without $\beta$-anomer formation on a multigram scale.

  • PDF

Immunopathogenesis of COVID-19 and early immunomodulators

  • Lee, Kyung-Yil;Rhim, Jung-Woo;Kang, Jin-Han
    • Clinical and Experimental Pediatrics
    • /
    • 제63권7호
    • /
    • pp.239-250
    • /
    • 2020
  • The novel coronavirus disease 2019 (COVID-19) is spreading globally. Although its etiologic agent is discovered as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there are many unsolved issues in COVID-19 and other infectious diseases. The causes of different clinical phenotypes and incubation periods among individuals, species specificity, and cytokine storm with lymphopenia as well as the mechanism of damage to organ cells are unknown. It has been suggested that in viral pneumonia, virus itself is not a direct cause of acute lung injury; rather, aberrant immune reactions of the host to the insults from viral infection are responsible. According to its epidemiological and clinical characteristics, SARS-CoV-2 may be a virus with low virulence in nature that has adapted to the human species. Current immunological concepts have limited ability to explain such unsolved issues, and a presumed immunopathogenesis of COVID-19 is presented under the protein-homeostasis-system hypothesis. Every disease, including COVID-19, has etiological substances controlled by the host immune system according to size and biochemical properties. Patients with severe pneumonia caused by SARS-CoV-2 show more severe hypercytokinemia with corresponding lymphocytopenia than patients with mild pneumonia; thus, early immunomodulator treatment, including corticosteroids, has been considered. However, current guidelines recommend their use only for patients with advanced pneumonia or acute respiratory distress syndrome. Since the immunopathogenesis of pneumonia may be the same for all patients regardless of age or severity and the critical immune-mediated lung injury may begin in the early stage of the disease, early immunomodulator treatment, including corticosteroids and intravenous immunoglobulin, can help reduce morbidity and possibly mortality rates of older patients with underlying conditions.

Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies

  • Rheenen, Hanna van;Rheenen, Patrick Ferry van
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제23권2호
    • /
    • pp.121-131
    • /
    • 2020
  • Purpose: To determine the long-term efficacy of the anti-tumor necrosis factor (TNF) agents, infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by performing a systematic literature review. Methods: An electronic search was performed in Medline, Embase, and the Cochrane Library from inception to September 26, 2019. Eligible studies were cohort studies with observation periods that exceeded 1 year. Studies that reported time-to-event analyses were included. Events were defined as discontinuation of anti-TNF therapy for secondary loss of response. We extracted the probabilities of continuing anti-TNF therapy 1, 2, and 3 years after initiation. Results: In total, 2,464 papers were screened, 94 were selected for full text review, and 13 studies (11 on IFX, 2 on ADA) met our eligibility criteria for inclusion. After 1 year, 83-97% of patients were still receiving IFX therapy. After 2 and 3 years the probability of continuing IFX therapy decreased to 67-91% and 61-85%, respectively. In total, 5 of the 11 studies subgrouped by concomitant medication consistently showed that the probabilities of continuing IFX therapy in patients with prolonged immunomodulator use were higher than those in patients on IFX monotherapy. Conclusion: This review of real-world evidence studies confirms the long-term therapeutic benefit of IFX therapy in diverse cohorts of children with luminal CD. Moreover, it supports the view that combination therapy with an immunomodulator prolongs the durability of IFX therapy in patients who previously failed to recover following first-line therapy. The limited number of time-to-event studies in patients on ADA prevented us from drawing definite conclusions about its long-term efficacy.

버섯의 항생물질(抗生物質) (Antibiotics from Mushrooms)

  • 황병호
    • Journal of Forest and Environmental Science
    • /
    • 제22권1호
    • /
    • pp.83-100
    • /
    • 2006
  • Antibiotics which produced by mushrooms discovered for last 40 years were described. Any antibiotic has not been used as infectious disease remudy but will be used as physiological active substance in near future. The antibiotic of mushrooms have not been published much in papers and do not have various finds of structures, compared to those of Streptomyces. Triple bond having compounds, terpenoid compounds aromatic compounds and some other compound have been known. These compounds are not dissolved well in water and mainly fat-soluble, except for cordycepin. Also, they are generally neutral, and some of them are acidic and almost none of them are basic compounds. However, acetylene and terpenoid compounds are the characteristic compounds of mushroom, and are not found in other microorganisms and plants. Especially, there are various terpenoid compounds in mushrooms. These metabolites of mushrooms were not used as antibiotic, but are interested as physiological active substance, such as enzyme inhibitor and immunomodulator. To promote studying on the antibiotics of mushroom, new screening methods must be developed, because strain belonged to the different genus produces different antibiotics, even though mushrooms belonged to the same genus and species. It is also known that mushrooms collected in different areas produce different antibiotics. Now, it is difficult to separate each pure compound from mushroom. It is important to find mushrooms which is impossible to cultivate artificially, or grow in the back land where is difficult to collect. Thousands of mushrooms grow on earth now, so that which species will be screened if not known. The biochemical and mycological study for usability of the metabolites of mushrooms is thought, as one of the important research areas, must be performed.

  • PDF

대식세포에서 산더덕에 의한 NO 생성 및 싸이토카인 유도효과 (Induction of Nitric Oxide and Cytokines in Macrophages by Codonopsis lanceolata)

  • 소미선;이진실;이세윤
    • 한국식품과학회지
    • /
    • 제36권6호
    • /
    • pp.986-990
    • /
    • 2004
  • 대식세포는 IL-1, IL-6, $TNF-{\alpha},\;IFN-{\gamma}$의 중요한 근원이고, 전염성의 병원체와 종양 세포에 대해 저항하는 주요한 effector 세포이다. 이것은 cytokine signal에 의해 세포파괴가 되도록 활성화 된다. 이번 연구에서 우리는 산더덕의 물 추출물이 cytokine, nitric oxide와 같은 effector 분자를 유도하기 위해 대식세포를 활성화하는지를 알아보기 위하여 실험하였다. 산더덕 추출물에 의한 대식세포의 NO 생성은 농도 의존적이고, 시간 의존적이었다. iNOS는 시간이 지날수록 발현이 유도되었다. 산더덕 추출물에 의한 IL-1과 IL-6 mRNA 유도는 시간 의존적으로 증가 되었고, 처리 후 24시간에 최고점에 도달하였다. 이것은 활성화된 대식세포가 종양세포를 죽일 수 있음을 말한다. $TNF-{\alpha}\;mRNA$의 양은 시간이 지나도 일정하였고, $IFN-{\gamma}\;mRNA$의 양은 산더덕 추출물의 처리 1시간 후에 빠르게 강화되었다. 이러한 결과로부터 산더덕은 효과적인 면역조절자이고 대식세포의 항종양활성을 강화함을 알 수 있다.

백작약 조다당분획에 의한 대식세포 활성화를 통한 암세포 증식 억제 (Inhibition of Tumor Growth through Macrophage Activation by Polysaccharide Fraction from Peonia japonica (PJ-P))

  • 박혜란;정우희;정일윤;이성태;조성기
    • 한국식품영양과학회지
    • /
    • 제32권1호
    • /
    • pp.149-154
    • /
    • 2003
  • 백작약은 한의학에서 보기ㆍ보혈을 위한 탕제에 이용되는 구성 생약재 중의 하나로서 본 연구에서는 백작약이 면역세포를 활성화시켜 암세포의 생장을 억제할 수 있는 능력이 있는지를 확인하고자 하였다. 그 결과 백작약 조다당분획(PJ-P)는 대식 세포를 활성화시켜 그 고유기능인 탐식 기능을 항진시켰다. 또한 암세포를 저해하는데 중요한 작용을 하는 NO와 TNF-$\alpha$, IL-1 그리고 IL-6의 분비를 향상시켰다. 이렇게 PJ-P에 의해 활성화된 대식 세포는 cytokine들과 NO를 생산함으로써 시험관 내에서 암세포를 살해하였으며, 또한 PJ-P는 암세포를 이식한 마우스의 생존기간을 연장시켰다 이같은 실험결과는 백작약의 조다당분획이 항암보조제 및 면역반응조절제로 활용될 가능성이 있음을 시사한다.

CKD-712, (S)-1-(${\alpha}$-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, Inhibits the NF-${\kappa}B$ Activation and Augments Akt Activation during TLR4 Signaling

  • Lee, Jeong-Gi;Yang, Eun-Jeong;Shin, Jeon-Soo;Kim, Dal-Hyun;Lee, Sung-Sook;Choi, In-Hong
    • IMMUNE NETWORK
    • /
    • 제11권6호
    • /
    • pp.420-423
    • /
    • 2011
  • Since CKD-712 has been developed as an anti-inflammatory agent, we examined the effect of CKD-712 during TLR4 signaling. Using HEK293 cells expressing TLR4, CKD-712 was pre-treated 1 hr before LPS stimulation. Activation of NF-${\kappa}B$ was assessed by promoter assay. The activation of ERK, JNK, p38, IRF3 and Akt was measured by western blotting. CKD-712 inhibited the NF-${\kappa}B$ signaling triggered by LPS. The activation of ERK, JNK, p38 or IRF3 was not inhibited by CKD-712. On the contrary the activation of these molecules was augmented slightly. The activation of Akt with stimulation of LPS was also enhanced with CKD-712 pre-treatment at lower concentration, but was inhibited at higher concentration. We suggest that during TLR4 signaling CKD-712 inhibits NF-${\kappa}B$ activation. However, CKD-712 augmented the activation of Akt as well as Map kinases. Therefore, we suggest that CKD-712 might have a role as an immunomodulator.

국내 염증성장질환의 약물치료 및 약제비 현황: 2010-2014 국민건강보험자료 활용 연구 (Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010-2014))

  • 하정은;장은진;임슬기;손현순
    • 한국임상약학회지
    • /
    • 제29권2호
    • /
    • pp.79-88
    • /
    • 2019
  • Backgrounds: Inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn's disease (CD) increased prevalence and economic burden. Objectives: This study aimed to investigate drug use pattern in IBD patients in a real world. Methods: National Health Insurance claim data from 2010 to 2014 were used in this population-based study. All IBD patients diagnosed during study period were enrolled. IBD medications included 5-aminosalicylic acid (ASA), glucocorticoid, immunomodulator and anti-tumor necrosis factor-${\alpha}$ agent(anti TNF-${\alpha}$). Growth rate of IBD prevalence, prescribed drug classes, duration of drug therapy and medication cost were analyzed. Number and percentage of patients for categorical variables, and mean and median for continuous variables were presented. Results: Total numbers of patients were 131,158 and 57,286 during 5 years, and their annual growth rate were 3.2 and 5.7% for UC and CD. UC and CD were prevalent in the 40-50 (41.2%) and 20-30 age groups (36.0%). About 60% of IBD patients was prescribed any of medications. 5-ASA was the most frequently prescribed, followed by corticosteroid and immunomodulator. Anti TNF-${\alpha}$ use was the lowest, but 5 times higher than UC in CD. Combination therapies with different class of drugs were in 29% for UC and 62% for CD. Mean prescription days per patient per year were 306 and 378, and the median medication cost per patient per year was KRW 420,000 (USD 383) and KRW 830,000 (USD755), for UC and CD, respectively. Conclusions: Increasing prevalence of IBD requires further studies to contribute to achieve better clinical outcomes of drug therapy.

Ginseng polysaccharides: Potential antitumor agents

  • Ruizhi, Tao;Keqin, Lu;Gangfan, Zong;Yawen, Xia;Hongkuan, Han;Yang, Zhao;Zhonghong, Wei;Yin, Lu
    • Journal of Ginseng Research
    • /
    • 제47권1호
    • /
    • pp.9-22
    • /
    • 2023
  • As a famous herbal medicine in China and Asia, ginseng (Panax ginseng C. A. Meyer) is also known as the "King of All Herbs" and has long been used in medicine and healthcare. In addition to the obvious biological activities of ginsenosides, ginseng polysaccharides (GPs) exhibit excellent antitumor, antioxidant stress, and immunomodulatory effects. In particular, GPs can exert an antitumor effect and is a potential immunomodulator. However, due to the complexity and diversity in the structures and components of GPs, their specific physicochemical properties, and underlying mechanisms remain unclear. In this article, we have summarized the factors influencing the antitumor activity of GPs and their mechanism of action, including the stimulation of the immune system, regulation of the gut microbiota, and direct action on tumor cells